Mangalam Drugs And Organics share price & results
- Jun 2026
- Sept 2026
Vapi (Gujarat)-based manufacturer of Anti-Malarial, Anti-Retroviral and other APIs, and among the world's largest suppliers of Anti-Malarial active pharmaceutical ingredients.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 57.1 | −0.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 1.6 | +9.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | -30.36 | −39.8 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -3.33 | −10.7 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -22.20 | −13.2 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −57.7% 1Y
1Y: ₹68.19 on 24 Oct 2025 → ₹28.82. High ₹68.19 (24 Oct 2025), low ₹23.78 (26 Dec 2025).
- Previous close
- ₹28.2
- Market cap
- ₹46 Cr
- 52-week range
- ₹23.78 – ₹67.96
- One year
- −57.59%
- Return on equity (TTM to Jun 2026)
- -30.36%
Overview
- Symbol
- NSE:MANGALAM
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Mangalam Drugs And Organics Limited does
Based on the company's own presentations, annual report and earnings calls.
Mangalam Drugs & Organics manufactures Active Pharmaceutical Ingredients (APIs), led by Anti-Malarial APIs such as Artemether, Lumefantrine, Artesunate and Amodiaquine Hydrochloride, sold to domestic formulators (Ajanta Pharma, Cipla, IPCA, Sun Pharma, Dr. Reddy's) and international clients (Sanofi, Guilin, Mylan, Merck). It has diversified into Anti-Retroviral APIs — Tenofovir Disoproxil Fumarate is commercialised, with several more molecules under validation or R&D — plus other APIs like Allopurinol, Nimesulide and Bisoprolol Fumarate. Manufacturing runs out of two units in Vapi, Gujarat, backward-integrated into key raw-material intermediates such as Lumefantrine and Sulfadoxine, and supported by an in-house R&D team. In FY25 the company expanded its anti-malaria portfolio with Pyronaridine, backed by WHO pre-qualification and a Medicines for Malaria Venture/Bill & Melinda Gates Foundation collaboration.
Segments
- Anti-Malarial APIs
- Anti-Retroviral APIs
- Other APIs
- Advanced intermediates
- Manufacturing units
- 2 (GIDC Vapi, Gujarat — Unit 1 & Unit 2)
- API manufacturing capacity
- ~1,080 TPA combined (Unit 1: 720 TPA, Unit 2: 360 TPA)
- Intermediates manufacturing capacity
- 1,000 TPA (Unit 2)
- WHO-approved Anti-Malarial APIs
- 7
- EDQM-approved APIs
- 2
- R&D scientists
- 20+
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 3 fiscal years held (Mar 2024 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +45% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 80 | 89 | 73 | 57 | 50 | 58 | 67 | 57 |
| Expenses | 71 | 80 | 63 | 62 | 52 | 60 | 73 | 56 |
| Operating profit | 9 | 9 | 10 | -5 | -3 | -2 | -5 | 1 |
| Operating margin | 10.9% | 9.9% | 13.6% | −8.1% | −5.7% | −2.7% | −8.0% | 1.6% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 4 | 3 | 4 | 4 | 5 | 4 | 3 | 4 |
| Depreciation | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 4 |
| Profit before tax | 1 | 1 | 2 | -13 | -12 | -10 | -13 | -7 |
| Tax rate | −125.2% | 5.4% | 90.8% | 6.2% | −41.4% | 0.0% | 1.2% | 13.4% |
| Net profit | 3 | 1 | 0 | -14 | -7 | -10 | -13 | -8 |
| EPS (₹ per share) | 1.70 | 0.88 | 0.09 | -8.67 | -4.58 | -6.18 | -8.25 | -4.77 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 369 | 318 | 232 |
| Expenses | 351 | 282 | 247 |
| Operating profit | 17 | 36 | -14 |
| Other income | 0 | 1 | 0 |
| Interest | 14 | 15 | 16 |
| Depreciation | 15 | 16 | 18 |
| Profit before tax | -11 | 5 | -48 |
| Net profit | -9 | 7 | -44 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 135 | 136 | 127 | 133 | 112 | 87 |
| Borrowings | 88 | 89 | 107 | 96 | 95 | 113 |
| Other liabilities | 90 | 117 | 108 | 114 | 94 | 92 |
| Total liabilities | 328 | 358 | 357 | 359 | 317 | 308 |
| Fixed assets | 135 | 142 | 147 | 156 | 159 | 148 |
| Capital work in progress | 6 | 9 | 8 | 3 | 4 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 188 | 206 | 202 | 201 | 155 | 156 |
| Total assets | 328 | 358 | 357 | 359 | 317 | 308 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operations | 12 | 43 | 4 |
| Cash from investing | -18 | -19 | -12 |
| Cash from financing | 6 | -22 | 6 |
| Net cash flow | 0 | 2 | -2 |
| Free cash flow | -6 | 23 | -8 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 52 | 38 | 46 | 28 | 45 | 63 |
| Inventory days | 85 | 139 | 200 | 185 | 303 | 239 |
| Days payable | 63 | 65 | 139 | 124 | 199 | 160 |
| Cash conversion cycle | 74 | 112 | 107 | 88 | 148 | 142 |
| Working capital days | 23 | 43 | 38 | 18 | 13 | -54 |
| Return on capital employed | 27.0% | 18.0% | 6.0% | 1.0% | 8.0% | −14.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Public hold 64.24% as of Sept 2026; institutions added 0.00 pts since Jun 2026.
- Promoters 35.65%
- Foreign institutions 0.11%
- Domestic institutions 0.00%
- Public 64.24%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- +2.25 pp 3.23% held
- newly disclosed 1.74% held
- newly disclosed 0.49% held
- +0.41 pp 1.42% held
The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Mangalam Drugs And Organics Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 6.21% | unchanged | |
| 6.00% | unchanged | |
| 3.23% | +2.25 pp | |
| 3.21% | unchanged | |
| 3.08% | unchanged | |
| 2.59% | unchanged | |
| 1.85% | unchanged | |
| 1.85% | unchanged | |
| 1.74% | newly disclosed | |
| 1.42% | +0.41 pp | |
| 1.21% | unchanged | |
| 1.03% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Mangalam Drugs And Organics Limited
Free account: one company. Everything above stays public.
Write why you follow Mangalam Drugs And Organics Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Mangalam Drugs And Organics Limited
Guides on how to read this kind of business and the numbers that matter.